Cardiovascular Systems Inc (CSII) was Upgraded by Leerink Partners to ” Outperform”. Earlier the firm had a rating of “Mkt Perform ” on the company shares. Leerink Partners advised their investors in a research report released on Aug 22, 2016.
Many Wall Street Analysts have commented on Cardiovascular Systems Inc. Company shares were Reiterated by Needham on Aug 4, 2016 to “Buy”, Firm has raised the Price Target to $ 27 from a previous price target of $23 .Cardiovascular Systems Inc was Upgraded by BofA/Merrill to ” Neutral” on Aug 4, 2016. Company shares were Reiterated by Needham on Jun 29, 2016 to “Buy”, Firm has raised the Price Target to $ 23 from a previous price target of $20 .
On the company’s financial health, Cardiovascular Systems Inc reported $-0.15 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Aug 3, 2016. Analyst had a consensus of $-0.20. The company had revenue of $48.50 million for the quarter, compared to analysts expectations of $46.01 million. During the same quarter in the previous year, the company posted $-0.27 EPS.
Cardiovascular Systems Inc closed down -0.06 points or -0.26% at $22.6 with 4,15,639 shares getting traded on Friday. Post opening the session at $22.54, the shares hit an intraday low of $22.1 and an intraday high of $22.67 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Aug 19, 2016, Paul A. Koehn (SVP Manufacturing & Operations) sold 4,000 shares at $22.17 per share price. According to the SEC, on Jun 1, 2016, Leslie Trigg (director) sold 3,500 shares at $33.86 per share price. On Jan 25, 2016, Scott R. Ward (CEO) purchased 2,700 shares at $9.30 per share price, according to the Form-4 filing with the securities and exchange commission.
Cardiovascular Systems Inc. is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary arterial diseases. It has developed an orbital atherectomy technology for peripheral and coronary commercial applications. Its peripheral arterial disease systems are catheter-based platforms that treat plaque types in leg arteries both above and below the knee. Its products include Stealth 360 degree Peripheral Orbital Atherectomy System (OAS); the Diamondback 360 Peripheral OAS (Diamondback 360 Peripheral) and Diamondback 360 Peripheral Diamondback 360 60cm Peripheral OAS and Diamondback 360 4 French 1.25 Peripheral (collectively called as peripheral arterial disease systems (PAD systems)). Its coronary product the Diamondback 360 Coronary OAS (CAD System) is a catheter-based platform designed to facilitate stent delivery in patients with coronary arterial disease (CAD). The CAD System design is customized for the coronary application.